A 53-year-old woman developed widespread tense bullae with pruritus and oral mucosal lesions recalcitrant to corticosteroids during a treatment with pembrolizumab for stage IV renal cell carcinoma that persisted after discontinuation of the drug. ESR and CRP levels were elevated and biopsy suggested an autoimmune bullous process, but direct immunofluorescence results were negative. What is the diagnosis and what would you do next?
This cohort study analyzed data from 2 large commercial insurance claims databases to characterize the incidence rate of bullous pemphigoid associated with the use of dipeptidyl peptidase–4 inhibitors.
This systematic review and meta-analysis assesses the association of the use of certain classes of medications among patients and the development of bullous pemphigoid.
This cross-sectional study of 125 residents of 7 nursing homes in the Netherlands evaluates the prevalence of pemphigoid as a potentially unrecognized cause of pruritus.
This case report describes a patient who experienced bullous, anti–laminin-332, and anti-p200 pemphigoid with concomitant anti–contactin-1–positive inflammatory polyneuropathy treated with intravenous immunoglobulins as a manifestation of epitope spreading.
This is a case report of a man who presented with oropharyngeal hemorrhage and impending airway compromise as the initial presentation of mucosal bullous pemphigoid.
This case series study of 6 patients describes the clinical and immunologic characteristics of bullous pemphigoid associated with transient palmoplantar keratoderma.
This case-control study examines the association between the use of dipeptidyl peptidase 4 inhibitors and the risk of developing bullous pemphigoid in patients with diabetes.
This cohort study examines the prevalence and distribution of mucosal involvement among patients with bullous pemphigoid.
This study analyzes the direct immunofluorescence and serologic data from 1125 consecutive patients for diagnosing pemphigoid, a cutaneous autoimmune disease that primarily affects older people.
This case-control study evaluates the association between use of dipeptidyl-peptidase 4 (DPP-4) inhibitors and development of bullous pemphigoid (BP) in patients with diabetes and characterizes those patients who develop DPP-4 inhibitor–associated BP.
You currently have no searches saved.
Create a personal account or sign in to: